|
🐜
|
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials
24 auth.
P. Sax,
D. Wohl,
M. Yin,
F. Post,
E. Dejesus,
M. Saag,
A. Pozniak,
M. Thompson,
D. Podzamczer,
J. Molina,
...
S. Oka,
E. Koenig,
B. Trottier,
J. Andrade-Villanueva,
G. Crofoot,
J. Custodio,
Andrew Plummer,
Lijie Zhong,
H. Cao,
Hal Martin,
C. Callebaut,
A. Cheng,
M. Fordyce,
S. McCallister
|
9 |
2015 |
9
🐜
|
|
🐜
|
Adaptation of HIV-1 to human leukocyte antigen class I
43 auth.
Yuka Kawashima,
K. Pfafferott,
J. Frater,
P. Matthews,
R. Payne,
M. Addo,
H. Gatanaga,
M. Fujiwara,
A. Hachiya,
Hirokazu Koizumi,
N. Kuse,
S. Oka,
A. Duda,
A. Prendergast,
H. Crawford,
...
A. Leslie,
Z. Brumme,
C. Brumme,
Todd M. Allen,
C. Brander,
R. Kaslow,
James Tang,
E. Hunter,
S. Allen,
J. Mulenga,
S. Branch,
T. Roach,
M. John,
S. Mallal,
A. Ogwu,
R. Shapiro,
J. Prado,
S. Fidler,
J. Weber,
O. Pybus,
P. Klenerman,
T. Ndung’u,
R. Phillips,
D. Heckerman,
P. Harrigan,
B. Walker,
M. Takiguchi,
P. Goulder
|
8 |
2009 |
8
🐜
|
|
🐢
|
Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens.
10 auth.
Kiyoto Tsuchiya,
H. Gatanaga,
N. Tachikawa,
K. Teruya,
Y. Kikuchi,
M. Yoshino,
...
T. Kuwahara,
T. Shirasaka,
S. Kimura,
S. Oka
|
8 |
2004 |
8
🐢
|
|
🐢
|
Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26.
20 auth.
H. Gatanaga,
Tsunefusa Hayashida,
Kiyoto Tsuchiya,
M. Yoshino,
T. Kuwahara,
H. Tsukada,
K. Fujimoto,
Isao Sato,
Mikio Ueda,
M. Horiba,
...
M. Hamaguchi,
Masahiro Yamamoto,
N. Takata,
A. Kimura,
T. Koike,
F. Gejyo,
S. Matsushita,
T. Shirasaka,
S. Kimura,
S. Oka
|
7 |
2007 |
7
🐢
|
|
🐜
|
Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection.
27 auth.
C. Orkin,
K. Arastéh,
M. Górgolas Hernández-Mora,
V. Pokrovsky,
E. Overton,
P. Girard,
S. Oka,
S. Walmsley,
Christopher Bettacchi,
C. Brinson,
P. Philibert,
Johan J. Lombaard,
M. S. St. Clair,
H. Crauwels,
S. L. Ford,
...
P. Patel,
Vasiliki Chounta,
R. D'Amico,
S. Vanveggel,
D. Dorey,
A. Cutrell,
Sandy Griffith,
D. Margolis,
P. Williams,
W. Parys,
Kimberly Smith,
W. Spreen
|
7 |
2020 |
7
🐜
|
|
🐜
|
Induction of IFN-λ3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection
19 auth.
K. Murata,
Mai Asano,
A. Matsumoto,
M. Sugiyama,
N. Nishida,
E. Tanaka,
Taisuke Inoue,
M. Sakamoto,
N. Enomoto,
Takayoshi Shirasaki,
...
M. Honda,
S. Kaneko,
H. Gatanaga,
S. Oka,
Y. Kawamura,
T. Dohi,
Y. Shuno,
H. Yano,
M. Mizokami
|
7 |
2016 |
7
🐜
|
|
🐜
|
Immunodeficiency at the Start of Combination Antiretroviral Therapy in Low-, Middle-, and High-Income Countries
75 auth.
Dorita Avila,
K. Althoff,
C. Mugglin,
K. Wools-Kaloustian,
Manuel Koller,
F. Dabis,
D. Nash,
T. Gsponer,
S. Sungkanuparph,
C. McGowan,
M. May,
D. Cooper,
C. Chimbetete,
M. Wolff,
A. Collier,
...
H. McManus,
M. Davies,
D. Costagliola,
B. Crabtree-Ramírez,
R. Chaiwarith,
A. Cescon,
M. Cornell,
L. Diero,
P. Phanuphak,
A. Sawadogo,
J. Ehmer,
S. Eholie,
P. Li,
M. Fox,
N. Gandhi,
E. González,
Christopher K. C. Lee,
C. Hoffmann,
A. Kambugu,
O. Keiser,
R. Ditangco,
H. Prozesky,
F. Lampe,
N. Kumarasamy,
M. Kitahata,
Emmanuel Lugina,
R. Lyamuya,
S. Vonthanak,
V. Fink,
A. d’Arminio Monforte,
P. Luz,
Yi‐Ming Arthur Chen,
A. Minga,
J. Casabona,
A. Mwango,
J. Choi,
M. Newell,
E. Bukusi,
K. Ngonyani,
T. Merati,
J. Otieno,
Mwebesa B Bosco,
S. Phiri,
O. Ng,
K. Anastos,
J. Rockstroh,
I. Santos,
S. Oka,
G. Somi,
C. Stephan,
R. Teira,
Deo Wabwire,
G. Wandeler,
A. Boulle,
P. Reiss,
R. Wood,
B. Chi,
C. Williams,
J. Sterne,
M. Egger
|
7 |
2013 |
7
🐜
|
|
🐢
|
HLA-Cw8 primarily associated with hypersensitivity to nevirapine.
9 auth.
H. Gatanaga,
H. Yazaki,
J. Tanuma,
M. Honda,
I. Genka,
K. Teruya,
...
N. Tachikawa,
Y. Kikuchi,
S. Oka
|
7 |
2007 |
7
🐢
|
|
🐢
|
Outbreak of Pneumocystis jiroveci Pneumonia in Renal Transplant Recipients: P. jiroveci Is Contagious to the Susceptible Host
H. Yazaki,
N. Goto,
K. Uchida,
Takaaki Kobayashi,
H. Gatanaga,
S. Oka
|
6 |
2009 |
6
🐢
|
|
🐬
|
Functional Expression of the Chemokine Receptor CCR5 on Virus Epitope-Specific Memory and Effector CD8+ T Cells1
K. Fukada,
Y. Sobao,
H. Tomiyama,
S. Oka,
M. Takiguchi
|
6 |
2002 |
6
🐬
|
|
🐜
|
Identification and characterization of multiple HLA-A24-restricted HIV-1 CTL epitopes: strong epitopes are derived from V regions of HIV-1.
7 auth.
Y. Ikeda-Moore,
H. Tomiyama,
K. Miwa,
S. Oka,
A. Iwamoto,
Y. Kaneko,
...
M. Takiguchi
|
6 |
1997 |
6
🐜
|
